Diaceutics PLC New Vice President of Finance appointment
04 March 2021 - 11:49PM
RNS Non-Regulatory
TIDMDXRX
Diaceutics PLC
04 March 2021
4 March 2021
Diaceutics PLC
("Diaceutics" or "the Company")
New Vice President of Finance appointment
Diaceutics PLC , ( AIM: DXRX), announces the appointment of
Nikita Lynn as Vice President of Finance. Nikita has been promoted
to this role following her tenure as Senior Director of Corporate
Advancement.
In her new role within Diaceutics, Nikita will be responsible
for the financial operations and corporate development of the
Company, reporting to the CFO, Board of Directors and Non-Executive
Directors. She brings extensive experience in financial reporting,
taxation and auditing for public companies to the position.
Before joining Diaceutics in August 2020, Nikita was a Senior
Manager at PwC where she spent approximately six years in the
Assurance Department, working predominantly within the audit team.
During this time, she also worked on reporting accountant
engagements, which included project leading the IPOs of Fusion
Antibodies in December 2017 and Diaceutics PLC in March 2019.
Nikita trained and qualified as a Chartered Accountant with the
Institute of Chartered Accountants, Ireland, and is an active
contributor with the Institute of Chartered Accountants Ireland,
Ulster Society, having gained experience across several committee
roles.
Commenting on the appointment, Philip White , Chief Financial
Officer of Diaceutics, said: "An expert in finance, Nikita has a
stellar track record and in-depth experience within the technology,
pharma, and manufacturing sectors. During her time as Senior
Director of Corporate Advancement at Diaceutics, she has
demonstrated the leadership abilities which will be invaluable in
helping us advance our mission and solutions enabled by DXRX - The
Diagnostic Network(R) , and in unlocking the transformative
financial value of platform business models."
Nikita Lynn, Vice President of Finance, Diaceutics added: "I'm
thrilled to commence a new chapter in my Diaceutics career, and to
continue working alongside a diverse group of talented
professionals aligned on a common goal - to provide every patient
with the treatment they deserve. I look forward to continuing to
work with the Diaceutics finance and executive management team as
we continue to drive the growth of Diaceutics PLC and DXRX."
Enquiries:
Diaceutics PLC
Philip White, Chief Financial Officer Via Walbrook PR
Cenkos Securities plc (Nomad & Broker) Tel: +44(0)20 7397
8900
Callum Davidson / Giles Balleny
Michael Johnson (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Tel: +44 (0)7876
741 001
Paul McManus Tel: +44 (0)7980
541 893
About Diaceutics
At Diaceutics we believe that every patient should get the
precision medicine they deserve. We are a data analytics and
end-to-end services provider enabled by DXRX - our Proprietary
Diagnostic Network solution for the development and
commercialisation of precision medicine diagnostics. The Company,
listed on the AIM Market of the London Stock Exchange, has created
commercially useful data sets for every precision medicine that has
come to market. We have built the world's largest repository of
diagnostic testing data with a growing network of 2,500
laboratories in 51 countries. www.diaceutics.com
About DXRX - The Diagnostic Network(R)
DXRX is the world's first diagnostic network for precision
medicine. DXRX is an end-to-end solution for the development and
commercialisation of Precision Medicine diagnostics. The platform
enables a vibrant marketplace where all stakeholders in Precision
Medicine come to find trusted partners and collaborations in a
secure, standardised way. DXRX provides access to a pipeline of
global diagnostic testing data on one secure platform.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRALZLFBFXLZBBV
(END) Dow Jones Newswires
March 04, 2021 07:49 ET (12:49 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024